Pseudomyxoma peritonei: a clinical case of this poorly understood condition by Oliveira, AM et al.
© 2014 de Oliveira. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of General Medicine 2014:7 137–141
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
137
C a s e  r e p o rt
open access to scientific and medical research
open access Full text article
http://dx.doi.org/10.2147/IJGM.S51504
pseudomyxoma peritonei: a clinical case  
of this poorly understood condition
ana Maria de oliveira1
Catarina Graça rodrigues1 
alexys Borges2 
alexandra Martins1
sofia Loureiro dos santos3
Francisco rocha pires4 
João Mascarenhas araújo2 
João ramos de Deus1
1Department of Gastroenterology, 
2Department of Internal Medicine, 
3Department of pathology and 
anatomical sciences, 4Department of 
surgery, pathology and anatomical 
sciences, prof. Doutor Fernando 
Fonseca Hospital, amadora, portugal 
Correspondence: ana Maria de oliveira 
IC 19, 2720-276 amadora, portugal 
tel +351 963 867 012 
Fax +351 214 345 566 
email anaoliveira.fml@gmail.com
Background: Pseudomyxoma peritonei is an uncommon condition with an estimated incidence 
of one to two per million (worldwide) per year. It is characterized by the peritoneal deposition 
of mucinous tumors, most commonly of the appendix, and occasionally from the ovary, coupled 
by mucinous ascites.
Case presentation: We report the case of a 76-year-old woman who presented with increased 
abdominal girth and dyspnea for 2 weeks. She was diagnosed as a case of pseudomyxoma 
peritonei. She was submitted to right oophorectomy, omentectomy, and pseudomyxoma 
debulking. The histology was compatible with a mucinous tumor of colorectal/appendicular 
origin. Chemotherapy was not administered because of her functional status. Two years and 
8 months later, she refers with postprandial fullness and has moderate ascites.
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Introduction
Pseudomyxoma peritonei (PMP) is a tumor with an estimated incidence of one to two 
million per year.1 It is a poorly understood disease that is known for its production 
of mucin in the abdominal cavity and mucinous implants, diffusely involving the 
peritoneal surfaces.2
The term PMP has been applied broadly and includes a heterogeneous group of 
pathological lesions from the benign to the borderline to the frankly malignant lesion.3,4 
Ronnett et al have suggested a classification based on tumor pathology in which they 
place all PMP in three groups in order of decreasing prognosis: disseminated perito-
neal adenomucinosis, peritoneal mucinous carcinoma with intermediate or discordant 
features, and peritoneal mucinous carcinoma.4
A definitive diagnosis of PMP requires the presence both of mucinous neoplastic cells/
epithelium and of mucinous ascites and diffuse intra-abdominal mucin. Some specialists 
also require the presence of diffuse mucinous implants for this diagnosis. Viable epithe-
lial glandular cells must be identified within the mucin pools by histological analysis to 
diagnose PMP. Cases without epithelium are regarded as mucinous ascites.5
Case report
A 76-year-old woman presented to our emergency department (Hospital Professor 
Doutor Fernando Fonseca, Amadora, Portugal) with dyspnea, increased abdominal 
girth, and peripheral edema for 2 weeks. Her medical history included diabetes mellitus 
type 2, hypertension, and dyslipidemia. She was medicated with ramipril, furosemide, 
aspirin, simvastatin, rabeprazole, and lorazepam.
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The physical examination revealed tachypnea, a blood 
pressure of 144/82 mmHg, a pulse rate of 83 beats per min-
ute (bpm), and apyrexia. Expiratory time was increased, and 
there were rales at the base of the lungs. The cardiovascular 
system did not reveal any remarkable changes. There was 
collateral venous circulation on the abdomen wall, the wall 
was slightly depressible, and percussion revealed tympanic 
resonance in the center of the abdomen and dullness in both 
lumbar regions. There was no palpable organomegaly or 
lymphadenopathy. Peripheral edema was present.
Laboratory investigations showed an absence of 
leukocytosis (8,400 leukocytes/µL) with neutrophilia 
(6,100 neutrophils/µL) and a C-reactive protein value 
of 6.21 mg/dL. The patient’s erythrocyte sedimentation 
rate was 88 mm, her carcinoembryonic antigen level was 
177 ng/mL (0–3 ng/mL), her cancer antigen 15–3 level 
was 55 U/mL (0–30 U/mL), her cancer antigen 125 level 
was 57.5 U/mL (0–35 U/mL), and her cancer antigen 19.9 
level was lower than 2.5 U/mL (0–37 U/mL).
Paracentesis was attempted but was unsuccessful. 
Abdomen ultrasonography and computed tomography 
showed images that were suggestive of pseudomyxoma and 
moderate, multiseptate ascites (Figure 1).
The patient was submitted to laparotomy with right 
oophorectomy, omentectomy, and pseudomyxoma debulking 
(Figure 2). At surgery, 6,200 g yellow-orange gelatinous 
material (Figure 3) was removed. The histological exami-
nation of biopsies (from small intestine, ovary, peritoneum, 
and epiploon) revealed mucinous neoplastic cells and diffuse 
intra-abdominal mucin, characteristics that allowed the 
diagnosis of PMP.
The morphological (Figure 4) and immunophenotypic 
(cytokeratin 7 focally positive [Figure 5], cytokeratin 20 dif-
fusedly positive [Figure 6], and p16 negative [Figure 7]) pat-
terns were compatible with colorectal/appendicular origin.
In the postoperative course, the patient had hemodynamic 
instability that reverted with fluid replacement and amines 
for a short period.
She was discharged in a satisfactory condition with 
follow-up at the oncology division. Because of her functional 
status, the patient has not received chemotherapy. The treat-
ment is being based on symptomatic relief.
Two years and 8 months later, she has referred occasion-
ally with postprandial fullness and moderate ascites. Her 
carcinoembryonic antigen and cancer antigen 125 levels 
are 133 ng/mL and 139 U/mL, respectively. The last image 
exam (abdomen ultrasonography) showed a small volume of 
perihepatic, perisplenic, and interloop fluid with peritoneal 
leaflets thickening. It was possible to identify a mass with 
58 × 30 mm in the left parietocolic groove, indicative of 
peritoneal carcinomatosis (Figure 8). Enlarged ganglia were 
Figure 1 Computed tomographic scan of abdomen showing pseudomyxoma 
peritonei with multiple peritoneal masses (arrow) with “scalloping effect.”
Figure 2 Laparotomy with right oophorectomy, omentectomy, and pseudomy-
xoma debulking.
Figure 3 Yellow-orange gelatinous material.
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also seen, the biggest of which was at the hepatic hilum, at 
32 mm (Figure 9).
Discussion
PMP was first described in 1842 by Karl F Rokitansky,6 but 
the term was used in 1884 in association with a mucinous 
carcinoma of the ovary.7 Later, in 1901, Franckel described 
PMP in association with an appendiceal cystic tumor.8
PMP is a disease of the MUC (a gel-forming mucin 
that forms strong bonds with the surrounding stroma and is 
also believed to have tumor-suppressor activities)9 express-
ing goblet cells that are specific for mucin production. 
Extracellular mucin accumulates dramatically and has no 
place to drain.4 A copious amount of mucinous fluid gradually 
fills the peritoneal cavity, resulting in the so-called “jelly 
belly” abdomen.5
The origin of PMP is a controversial subject.10 Most 
acknowledge that PMP predominantly originates in the 
Figure 4 Hematoxylin and eosin staining (×20).
Figure 5 Cytokeratin 7 focally positive staining (×10).
Figure 6 Cytokeratin 20 diffusely positive staining (×10).
Figure 7 p16-negative staining (×10).
Figure 8 abdomen ultrasonography showing a mass with 58 × 30 mm in the left 
parietocolic groove.
Figure 9 abdomen ultrasonography showing a ganglion with 32 mm at 
hepatic hilum.
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appendix in men, and increasingly, evidence suggests a 
similar origin in women. In women, synchronous ovarian 
and appendiceal disease is common. However, immuno-
histochemistry and molecular genetic techniques support 
the hypothesis that in the majority of women, the ovarian 
tumor is metastatic from a perforated appendiceal muci-
nous tumor.1 This hypothesis is illustrated by the presented 
case, as histological analysis of the oophorectomy piece 
revealed a pattern compatible with colorectal/appendicular 
origin.
The reported sex distribution is contradictory in the 
literature: some authors have noted a significant preponder-
ance of women5,8,10 whereas others found no difference.3 
However, as some authors highlight, it is improbable that the 
female preponderance found in some studies has a biological 
explanation; instead, the effect is more likely the result of 
some referral bias, possibly resulting from the use of itera-
tive surgery in secondary care hospitals to treat male patients 
with PMP and not referring them to a tertiary unit. Female 
patients were more likely to be referred because of presumed 
ovarian malignancy requiring complex procedures available 
only in tertiary care units.1,10
The symptoms of this uncommon disease are nonspecific; 
the most commonly recorded are abdominal pain10 resem-
bling acute appendicitis, distension,10,11 or mass.12 Nausea, 
vomiting, and asthenia have also been described.13 In rare 
cases, the mucinous collection can lead to signs of raised 
intra-abdominal pressure, such as uterine prolapse or 
abdominal hernia.10
In addition to symptoms being nonspecific, routine 
laboratory studies also are seldom helpful in making this 
diagnosis.5
An accurate preoperative diagnosis of PMP can be aided 
by radiological imaging,5 with a computed tomography 
scan being the currently optimal imaging modality for the 
diagnosis and staging of this disease. Computed tomography 
scan findings may be pathognomonic. Typical appearances 
include areas of low attenuation, with islands of higher 
attenuation resulting from solid elements within mucinous 
material. Classically, “scalloping” of visceral surfaces, 
particularly of the liver and spleen, distinguishes mucinous 
from fluid ascites.1
However, diagnosis of PMP is challenging because of 
the mimicking nature of the disease. In the study conducted 
by Järvinen and Lepistö, only 28% of patients underwent 
initial surgery for presumed PMP.10 Preoperative diagnosis 
is often appendicitis,1 gynecological cancer1/ovarian tumor,10 
or peritonitis,1 which did not happen in our case, as imaging 
suggested from the beginning a diagnosis of PMP.
A treatment strategy for PMP should pursue complete 
cytoreduction and prevention of recurrence or progression. 
Combined modality treatment, consisting of cytoreductive 
surgery with hyperthermic intraperitoneal chemotherapy, 
seems very efficient in this regard.14–17 This approach is cur-
rently carried out in many centers throughout the world, with 
promising results,18 and seems to win ground as the standard 
treatment approach.14
However, not all cases are suitable for this approach.10 
Patients must be medically fit to safely undergo these treat-
ments, and patients with peritoneal carcinomatosis with an 
Eastern Cooperative Oncology Group (ECOG) performance 
score of 2 to 3 have significantly poorer overall survival 
after the treatment compared with those with an ECOG 
score of 1.1
In the presented case, the patient had an ECOG perfor-
mance status of 3; therefore, we considered her to be not 
medically fit to be submitted to the referred approach.
Unfortunately, the majority of patients develop recur-
rence after treatment,19 which requires repeated surgical 
intervention.6 Elevated tumor markers such as carcinoem-
bryonic antigen level, cancer antigen 19-9 level, and cancer 
antigen 125 level indicate advanced disease and may rise in 
association with recurrent disease.12,20
Surgical reintervention is usually difficult because adhe-
sions and fibrosis greatly increase the risk of unintentional 
enterotomies with subsequent leaks and fistulae formation; 
it is, however, widely accepted that recurrences should be 
investigated vigorously and treated with further surgical 
debulking, with or without adjuvant chemotherapy, in the 
expectation that many patients will enjoy substantial addi-
tional symptom-free survival.6
The reported prognostic factors of PMP are age,21 
histology,11 residual tumor volume,11 and intraperitoneal 
chemotherapy.13
An interesting fact is that chemotherapy may improve 
survival only if administered intraperitoneally,13,19 as reported 
by the Mayo Clinic, Gough DB.13 Systemic chemotherapy 
seems not to affect prognosis.19
In addition, survival rates differ greatly according to 
histology: Ronnett et al observed 5- and 10-year survival 
rates of 75% and 68%, respectively, for cases of disseminated 
peritoneal adenomucinosis; 50% and 21%, respectively, 
for cases of intermediate malignancy; and 14% and 3%, 
respectively, for peritoneal mucinous carcinoma.22
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Conclusion
We described a case of a female patient who developed 
PMP, a rare and heterogeneous condition for which the 
diagnosis is often misleading in the preoperative period.
In the light of current knowledge, the optimal treatment 
involves a combination of surgery and hyperthermic intra-
peritoneal chemotherapy.
Awareness of this condition, although it is rare, is an 
important prerequisite for appropriate management, as the 
long-term outcomes for cytoreductive surgery with hyper-
thermic intraperitoneal chemotherapy are impressive for 
patients with low-grade histology susceptible to complete 
cytoreduction.
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